Quantinno Capital Management LP Boosts Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Quantinno Capital Management LP raised its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 268.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 58,913 shares of the specialty pharmaceutical company's stock after acquiring an additional 42,924 shares during the quarter. Quantinno Capital Management LP owned approximately 0.10% of Jazz Pharmaceuticals worth $6,563,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Itau Unibanco Holding S.A. bought a new position in Jazz Pharmaceuticals during the second quarter worth about $29,000. EverSource Wealth Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock worth $30,000 after acquiring an additional 97 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock worth $31,000 after acquiring an additional 116 shares during the last quarter. Gladius Capital Management LP acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth approximately $33,000. Finally, Venturi Wealth Management LLC increased its holdings in shares of Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company's stock worth $92,000 after acquiring an additional 704 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the transaction, the chief executive officer now directly owns 427,025 shares in the company, valued at approximately $51,742,619.25. The trade was a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the business's stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now owns 33,048 shares of the company's stock, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,753 shares of company stock worth $816,289 over the last 90 days. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Stock Down 0.4 %

Jazz Pharmaceuticals stock traded down $0.55 during mid-day trading on Friday, reaching $122.59. The stock had a trading volume of 271,650 shares, compared to its average volume of 683,863. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.17. The stock's 50-day simple moving average is $116.18 and its 200-day simple moving average is $111.56. The firm has a market capitalization of $7.41 billion, a PE ratio of 17.27, a price-to-earnings-growth ratio of 1.04 and a beta of 0.57.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on JAZZ. TD Cowen decreased their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Robert W. Baird boosted their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an "outperform" rating in a report on Monday, November 18th. Royal Bank of Canada upped their price objective on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an "outperform" rating in a report on Wednesday, October 23rd. JPMorgan Chase & Co. upped their price objective on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an "overweight" rating in a report on Monday, August 19th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $175.33.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.